Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF(V600) mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial

Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Goppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D (2021)

Publication Type: Journal article

Publication year: 2021

Journal

European Journal of Cancer Elsevier

Book Volume: 158

Pages Range: 72-84

DOI: 10.1016/j.ejca.2021.09.011

Abstract

Background: Combination of immune checkpoint inhibitors and mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-tumour responses induced by MAPKi. Here, we present phase I safety results from an open-label, phase I/II study of pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) triplet therapy in advanced, B-Raf proto-oncogene serine/threonine kinase (BRAF)(V600)-mutated melanoma (IMMU-TARGET, NCT02902042).

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Technische Universität München (TUM) DE Germany (DE) Justus-Liebig-Universität Gießen DE Germany (DE) HELIOS Kliniken DE Germany (DE) Medizinische Hochschule Brandenburg "Theodor Fontane" / Brandenburg Medical School "Theodor Fontane" DE Germany (DE) Alcedis GmbH DE Germany (DE)

How to cite

APA:

Zimmer, L., Livingstone, E., Krackhardt, A., Schultz, E.S., Goppner, D., Assaf, C.,... Schadendorf, D. (2021). Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF(V600) mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. European Journal of Cancer, 158, 72-84. https://doi.org/10.1016/j.ejca.2021.09.011

MLA:

Zimmer, Lisa, et al. "Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF(V600) mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial." European Journal of Cancer 158 (2021): 72-84.

BibTeX: Download